Navigation Links
Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
Date:5/5/2011

ial," or similar expressions, or by express or implied discussions regarding potential submissions or approvals for new indications or labeling for Afinitor, or regarding the potential timing of any such submissions or approvals, or regarding potential future revenues from Afinitor. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Afinitor to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Afinitor will be submitted or approved for any additional indications or labeling in any market. Nor can there be any guarantee that Afinitor will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Afinitor could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; government, industry and general public pricing pressures; competition in general; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date an
'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
2. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
3. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
4. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
5. Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
6. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
7. Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
8. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
9. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
10. Novartis to Expand Global Research Headquarters in Cambridge, MA
11. VIDEO From thenewsmarket.com and Novartis: Phase III Data Show That Novartis Meningococcal Vaccine Menveo® Demonstrated Robust Immunogenicity in Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex ... it will report its second quarter 2015 financial results ... a conference call and live webcast at 4:30 p.m. ... clinical development programs and a general corporate update. ... the Investor Relations page of the OncoGenex website at ...
(Date:7/30/2015)... N.J., July 30, 2015 PTC Therapeutics, Inc. ... and reported financial results for the second quarter ending ... on many fronts across the organization.  We are excited ... muscular dystrophy clinical trial ever conducted with topline results ... Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is ...
(Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... , WOODCLIFF LAKE, N.J. , May 10 ... today announced that its partner, Glenmark Generics Limited and Glenmark ... agreement with Merck & Co. Inc. that resolves patent litigation ... This settlement effectively ends the lawsuit involving a challenge by ...
... BEIJING , May 10 ... nearly,two-year trial, the ten arbitration cases with Beijing Un-Assegai Technical ... distributor,of clinical diagnostic products in China , as claimant ... as respondent have been decided by the,China International Economic and ...
Cached Medicine Technology:Par's Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To Settle Patent Litigation Over Generic ZETIA(R) 2Assegai Wins Big Settlement Against ABBOTT's Subsidiary 2
(Date:7/31/2015)... ... July 31, 2015 , ... ... What are the STASH awards? The Significant Technological Achievements in Secretive Horticulture ... community as well as tried-and-true products that have stood the test of time. ...
(Date:7/31/2015)... ... ... Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA on Sunday, February ... In the two weeks that separate the conference championships and the Super Bowl, there is ... will mark the 50th time it has been held and the festivities will take place ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... its new store run by GoodThreads. The store can be accessed by visiting ... designs, many of which are customizable. The best part: whenever a product is ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug and ... True North Conference Center. The medical community, social workers, law enforcement, and government ... more aligned in the effort to better understand and combat sex trafficking. Lead ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source of ... catch a new and refreshing show on Broadway, look no further than Hamilton. This ... Obie Award, Outer Critics Circle Award, Drama Desk Award, Lucille Lortel Award, and New ...
Breaking Medicine News(10 mins):Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7
... ... question the impact the silver screen’s ageless face has on mainstream America. , ... Anaheim, Calif. (PRWEB) December ... actresses. Carla Gugino, an actress of Night at the Museum, Race to Witch ...
... ... based in Texas, announced today that it has expanded its’ continuum of care with the ... ... Recovery, LLC announced today that it has expanded its’ continuum of care to include Origins ...
... ... , ... pages contained within HR 3200, the House Bill that the recently passed Senate Health Care ... to a cooperative effort between Hearthebill.org and iScroll , developers of the evolutionary new ...
... , Department of Health Urges All Pennsylvanians to Get Vaccinated ... Disease Control and Prevention, or CDC, has allocated a total ... date, the state Department of Health said today. , ... health departments, and state health centers. , The ...
... Calif., Dec. 28 With the New Year just around the ... , Lose weight., Exercise more., ... of most New Year,s resolutions is health-related, many tend to forget ... the doctor. Even more so, we forgo the regular visits to ...
... a role for enhanced activation of the signaling protein ... TSC1 or the TSC2 protein. As indicated by Warren ... accompanying commentary, these data provide a rationale for testing ... TSC-associated tumors. Tuberous sclerosis complex (TSC) is a ...
Cached Medicine News:Health News:Dermatologists Dissect Hollywood's Ageless Face Obsession 2Health News:Origins Recovery Centers Announces an Expansion of its Continuum of Care 2Health News:Origins Recovery Centers Announces an Expansion of its Continuum of Care 3Health News:House Health Care Bill Becomes Up To 38% More Understandable 2Health News:Celebrate the New Year With a New You 2
... one of the world's thinnest, ... a 7 F introducer, the ... designed to lower the incidence ... introduction in smaller, more tortuous ...
... fixation lead series are silicone endocardial ... helix mechanism, specifically designed for optimal ... reducing the sensing of far-field R ... fixation leads allow a higher sensitivity ...
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
The Guidant Fineline II EZ Sterox with protective capsule is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Medicine Products: